MCID: VSC003
MIFTS: 56

Visceral Leishmaniasis malady

Categories: Infectious diseases

Aliases & Classifications for Visceral Leishmaniasis

Aliases & Descriptions for Visceral Leishmaniasis:

Name: Visceral Leishmaniasis 12 14
Leishmaniasis, Visceral 42 69
Kala-Azar 12 3
Infection by Visceral Leishmaniasis 12
Leishmaniasis Visceral 52

Classifications:



External Ids:

Disease Ontology 12 DOID:9146
ICD10 33 B55.0 B55.9
ICD9CM 35 085.0
MeSH 42 D007898
NCIt 47 C34771
SNOMED-CT 64 186803007 48115004
UMLS 69 C0023290

Summaries for Visceral Leishmaniasis

CDC : 3 Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. It is classified as a Neglected Tropical Disease (NTD). Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of phlebotomine sand flies. There are several different forms of leishmaniasis in people. The most common forms are cutaneous leishmaniasis, which causes skin sores, and visceral leishmaniasis, which affects several internal organs (usually spleen, liver, and bone marrow).

MalaCards based summary : Visceral Leishmaniasis, also known as leishmaniasis, visceral, is related to hepatitis and tuberculosis. An important gene associated with Visceral Leishmaniasis is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs deoxycholic acid and Amphotericin B have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver, and related phenotypes are cellular and digestive/alimentary

Disease Ontology : 12 A leishmaniasis that is the most severe form of the disease caused by protozoan parasites of the Leishmania genus, resulting in the infection of the internal organs such as liver, spleen and bone marrow. The symptoms include fever, weight loss, and an enlarged spleen and liver.

Wikipedia : 71 Visceral leishmaniasis (VL), also known as kala-azar,black fever, and Dumdum fever, is the most severe... more...

Related Diseases for Visceral Leishmaniasis

Diseases related to Visceral Leishmaniasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 289)
id Related Disease Score Top Affiliating Genes
1 hepatitis 30.3 IFNG IL10 IL2 TNF
2 tuberculosis 29.8 IL10 IL2 IL4 TLR9 TNF
3 polyarteritis nodosa 29.7 IFNG TLR2 TLR4 TLR9
4 splenic marginal zone lymphoma 29.5 NOS2 TGFB1 TNF
5 membranoproliferative glomerulonephritis 29.1 ALB FOXP3 IL10 IL2 IL4 TLR9
6 rheumatoid arthritis 29.1 FOXP3 IFNG IL10 IL2 IL4 SLC11A1
7 leishmaniasis 12.1
8 myoglobinuria recurrent 10.4 IFNG IL4
9 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
10 asymptomatic neurosyphilis 10.3 IFNG IL10 IL4
11 tungiasis 10.3 IFNG IL10 IL4
12 congenital dyserythropoietic anemia 10.3 ALB TNF
13 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 IL4 TNF
14 lagophthalmos 10.3 IL10 IL4 TNF
15 conidiobolomycosis 10.3 IL10 IL4 TNF
16 ethmoid sinus cancer 10.3 IFNG SLC11A1 TLR4
17 urethral intrinsic sphincter deficiency 10.3 IFNG IL4 TNF
18 vestibule of mouth cancer 10.3 IL10 IL4 TNF
19 hypotrichosis 4 10.3 IFNG IL4 TNF
20 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.3 IFNG IL2 IL4
21 senile reticular retinal degeneration 10.3 IFNG IL10 TNF
22 conduct disorder 10.3 IFNG IL10 TNF
23 pancreatic signet ring cell adenocarcinoma 10.3 IFNG IL10 TNF
24 steatitis 10.3 IL2 TNF
25 ciliary discoordination, due to random ciliary orientation 10.3 ALB IFNG IL10
26 paralytic poliomyelitis 10.3 IFNG IL2 TLR4
27 erb-duchenne and dejerine-klumpke palsies 10.3 IFNG IL10 TNF
28 sarcomatoid transitional cell carcinoma 10.3 IL10 SLC11A1 TNF
29 rosacea 10.3 ALB IFNG IL10
30 oral cavity cancer 10.3 IFNG IL4 TNF
31 gonococcal endophthalmia 10.3 IL10 IL4 TNF
32 duodenal somatostatinoma 10.3 IL4 SLC11A1 TLR4
33 primary ciliary dyskinesia 10.3 IL10 SLC11A1 TNF
34 central nervous system origin vertigo 10.3 IFNG IL2 IL4
35 red cell phospholipid defect with hemolysis 10.3 IFNG IL4 TNF
36 proximal symphalangism 10.3 IFNG IL10 IL4
37 parametritis 10.3 IFNG IL2 TNF
38 non-gestational choriocarcinoma 10.3 ALB IFNG IL10
39 oropharynx cancer 10.3 IFNG IL10 IL2
40 leukoplakia of penis 10.3 IL10 IL4 TLR2
41 venezuelan hemorrhagic fever 10.3 IFNG IL2 TNF
42 refractory celiac disease 10.3 IL10 TGFB1
43 follicular adenoma 10.3 IFNG IL10 TNF
44 lung combined large cell neuroendocrine carcinoma 10.3 IL10 IL2 IL4
45 hypertropia 10.2 ALB IFNG TNF
46 centronuclear myopathy 5 10.2 IFNG IL10 IL4 SLC11A1
47 benign deep fibrous histiocytoma 10.2 ALB IFNG TNF
48 nystagmus, congenital motor, autosomal recessive 10.2 SLC11A1 TLR2 TNF
49 spotted fever 10.2 TLR2 TLR4 TNF
50 acquired polycythemia 10.2 IL10 IL4 TNF

Graphical network of the top 20 diseases related to Visceral Leishmaniasis:



Diseases related to Visceral Leishmaniasis

Symptoms & Phenotypes for Visceral Leishmaniasis

MGI Mouse Phenotypes related to Visceral Leishmaniasis:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 ALB EEF2 FOXP3 IFNG IFNGR1 IL10
2 digestive/alimentary MP:0005381 10.41 ALB FOXP3 IFNG IFNGR1 IL10 IL2
3 hematopoietic system MP:0005397 10.38 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
4 homeostasis/metabolism MP:0005376 10.37 TNF TPI1 ALB FOXP3 IFNG IFNGR1
5 immune system MP:0005387 10.36 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
6 mortality/aging MP:0010768 10.36 ALB EEF2 FOXP3 IFNG IFNGR1 IL10
7 growth/size/body region MP:0005378 10.33 EEF2 FOXP3 IFNG IL10 IL2 IL4
8 behavior/neurological MP:0005386 10.3 FOXP3 IFNG IFNGR1 IL10 IL2 NOS2
9 endocrine/exocrine gland MP:0005379 10.3 ALB FOXP3 IFNG IFNGR1 IL10 IL2
10 cardiovascular system MP:0005385 10.29 IL10 IL2 NOS2 TGFB1 TLR2 TLR4
11 liver/biliary system MP:0005370 10.26 TLR4 TNF ALB FOXP3 IFNG IFNGR1
12 integument MP:0010771 10.19 FOXP3 IFNG IFNGR1 IL10 IL4 NOS2
13 neoplasm MP:0002006 10.14 ALB IFNG IFNGR1 IL10 IL2 NOS2
14 craniofacial MP:0005382 10.12 FOXP3 IFNG IL10 IL4 NOS2 TGFB1
15 muscle MP:0005369 10.03 ALB IFNG IL10 NOS2 TGFB1 TLR2
16 renal/urinary system MP:0005367 10.02 ALB FOXP3 IFNG IFNGR1 IL4 NOS2
17 normal MP:0002873 9.97 TPI1 ALB FOXP3 IFNG IL10 IL4
18 reproductive system MP:0005389 9.96 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
19 respiratory system MP:0005388 9.85 IL4 NOS2 TGFB1 FOXP3 IFNG IL10
20 skeleton MP:0005390 9.65 TGFB1 TLR2 IFNG IFNGR1 IL10 IL4
21 vision/eye MP:0005391 9.28 FOXP3 IFNG IL10 IL2 IL4 NOS2

Drugs & Therapeutics for Visceral Leishmaniasis

Drugs for Visceral Leishmaniasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
deoxycholic acid Approved Phase 4,Phase 3 83-44-3 222528
2
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1397-89-3 14956 5280965
3
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Paromomycin Approved, Investigational Phase 4,Phase 3,Early Phase 1 1263-89-4, 7542-37-2 165580
6
Miltefosine Approved Phase 4,Phase 3,Phase 2,Phase 1 58066-85-6 3600
7 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
8 meglumine antimoniate Phase 4,Early Phase 1
9 Cholagogues and Choleretics Phase 4,Phase 3
10 Gastrointestinal Agents Phase 4,Phase 3
11 Amphotericin B, deoxycholate drug combination Phase 4,Phase 3
12 Anesthetics Phase 4
13 Anthelmintics Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
16 Liposomal amphotericin B Phase 4,Phase 3,Phase 2,Phase 1
17 Antimony Sodium Gluconate Phase 4,Phase 3,Phase 2,Phase 1
18 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20
Pentamidine Approved Phase 3 100-33-4 4735
21
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
22 Adjuvants, Immunologic Phase 2, Phase 3
23 Aluminum sulfate Phase 2, Phase 3
24 Vaccines Phase 2, Phase 3, Phase 1
25 Vitamins Phase 3
26 Tocopherols Phase 3
27 Tocotrienols Phase 3
28 Tocopherol Nutraceutical Phase 3
29 Tocotrienol Nutraceutical Phase 3
30 Soybean oil, phospholipid emulsion Phase 2
31 Parenteral Nutrition Solutions Phase 2
32 Pharmaceutical Solutions Phase 2
33 Immunoglobulins Phase 1, Phase 2
34 Fat Emulsions, Intravenous Phase 2
35 Antibodies Phase 1, Phase 2
36 Soy Bean Nutraceutical Phase 2
37 Thromboplastin Phase 1
38
Acetylcysteine Approved, Investigational 616-91-1 12035
39
Zinc Approved 7440-66-6 32051 23994
40
Erythromycin Approved, Vet_approved 114-07-8 12560
41
Iron Approved 7439-89-6 23925
42
Neomycin Approved, Vet_approved 1404-04-2 8378
43
Albendazole Approved, Vet_approved 54965-21-8 2082
44
Coal tar Approved 8007-45-2
45
Vitamin A Approved, Nutraceutical, Vet_approved 11103-57-4, 68-26-8 445354
46 N-monoacetylcystine
47 Expectorants
48 Protective Agents
49 Antidotes
50 Respiratory System Agents

Interventional clinical trials:

(show top 50) (show all 54)
id Name Status NCT ID Phase
1 Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children Completed NCT01032187 Phase 4
2 Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis Completed NCT00604955 Phase 4
3 A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL) Completed NCT01975051 Phase 4
4 Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India Completed NCT01661296 Phase 4
5 Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis Not yet recruiting NCT01566552 Phase 4
6 Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil Terminated NCT01310738 Phase 4
7 To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar Completed NCT00876824 Phase 3
8 An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis Completed NCT00629031 Phase 3
9 Combination Therapy in Indian Visceral Leishmaniasis Completed NCT00523965 Phase 3
10 Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis Completed NCT00628719 Phase 3
11 Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis Completed NCT00216346 Phase 3
12 Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis Completed NCT00696969 Phase 3
13 Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients With Pentamidine: a Cohort Study Completed NCT01360762 Phase 3
14 Replacement of Insecticides to Control Visceral Leishmaniasis (VL) Completed NCT01644682 Phase 3
15 Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis Completed NCT00255567 Phase 3
16 Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh Completed NCT01122771 Phase 3
17 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With no Response to Leishmanin Completed NCT00429715 Phase 2, Phase 3
18 Safety/Efficacy Trial of Killed Leishmania Vaccine in Volunteers With Positive Response to Leishmanin (LST>0) Completed NCT00429780 Phase 2, Phase 3
19 Miltefosine for Children With PKDL Recruiting NCT02193022 Phase 3
20 Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients. Active, not recruiting NCT02011958 Phase 3
21 Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa Not yet recruiting NCT03129646 Phase 3
22 A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar Completed NCT00497601 Phase 2
23 Combination Chemotherapy for the Treatment of Indian Kala-Azar Completed NCT00370825 Phase 2
24 Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar Completed NCT00371995 Phase 2
25 A Study Evaluating Sitamaquine Compared With Amphotericin B In The Treatment Of Visceral Leishmaniasis. Completed NCT00381394 Phase 2
26 Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa Completed NCT01067443 Phase 2
27 Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa Completed NCT02431143 Phase 2
28 Sodium Stibogluconate Treatment of Leishmaniasis Completed NCT00662012 Phase 2
29 Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL) Completed NCT01635777 Phase 2
30 Use of Sodium Stibogluconate as a Treatment for Leishmaniasis Completed NCT00657618 Phase 1, Phase 2
31 A Study of a New Leishmania Vaccine Candidate ChAd63-KH Recruiting NCT02894008 Phase 2
32 Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨ Recruiting NCT02687971 Phase 2
33 Miltefosine for Brazilian Visceral Leishmaniasis Terminated NCT00378495 Phase 1, Phase 2
34 Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan Terminated NCT01980199 Phase 2
35 Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL Terminated NCT00832208 Phase 2
36 SCH708980 With and Without AmBisome for Visceral Leishmaniasis Withdrawn NCT01437020 Phase 1, Phase 2
37 Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India Completed NCT00486382 Phase 1
38 Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers Completed NCT02071758 Phase 1
39 Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL Completed NCT00982774 Phase 1
40 Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers Completed NCT01484548 Phase 1
41 Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine Unknown status NCT01138956
42 A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh Completed NCT01240473
43 Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia Completed NCT02148822
44 Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar Completed NCT00318721
45 Amphotericin B Treatment in Visceral Leishmaniasis Completed NCT00310505
46 Immunogenetics of Visceral Leishmaniasis Completed NCT00342823
47 An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh Completed NCT01328457
48 A Community Trial for Visceral Leishmaniasis (VL) Completed NCT01069198
49 Clinical Investigation of Infections Due to Leishmanial Parasites Completed NCT00001169
50 Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) Completed NCT01766830

Search NIH Clinical Center for Visceral Leishmaniasis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leishmaniasis, visceral

Genetic Tests for Visceral Leishmaniasis

Anatomical Context for Visceral Leishmaniasis

MalaCards organs/tissues related to Visceral Leishmaniasis:

39
Bone, Bone Marrow, Liver, Spleen, Testes, Skin, T Cells

Publications for Visceral Leishmaniasis

Articles related to Visceral Leishmaniasis:

(show top 50) (show all 789)
id Title Authors Year
1
Diagnosis of Mediterranean visceral leishmaniasis by detection of Leishmania-related antigen in urine and oral fluid samples. ( 28017861 )
2017
2
Immunization with Leishmania donovani protein disulfide isomerase DNA construct induces Th1 and Th17 dependent immune response and protection against experimental visceral leishmaniasis in Balb/c mice. ( 28064069 )
2017
3
Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field. ( 28063460 )
2017
4
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. ( 28066878 )
2017
5
Comparative genomics of canine-isolated Leishmania (Leishmania) amazonensis from an endemic focus of visceral leishmaniasis in Governador Valadares, southeastern Brazil. ( 28091623 )
2017
6
Adenosine generated by ectonucleotidases modulates the host immune system during visceral leishmaniasis. ( 28082236 )
2017
7
Scoring clinical signs can help diagnose canine visceral leishmaniasis in a highly endemic area in Brazil. ( 28076469 )
2017
8
The anti-tubercular drug delamanid as a potential oral treatment for visceral leishmaniasis. ( 27215734 )
2016
9
NOD2-RIP2-mediated signalling contributes to shape adaptive immunity in visceral leishmaniasis. ( 27651416 )
2016
10
Xenodiagnosis on dogs with visceral leishmaniasis: Canine and sand fly aspects related to the parasite transmission. ( 27198788 )
2016
11
Pharmacovigilance of Miltefosine in Treatment of Visceral Leishmaniasis in Endemic Areas of Bihar, India. ( 27645786 )
2016
12
IL-18 gene polymorphism in patients with visceral leishmaniasis in East Azarbaijan, Iran. ( 27605823 )
2016
13
Supplementation of host response by targeting nitric oxide to the macrophage cytosol is efficacious in the hamster model of visceral leishmaniasis and adds to efficacy of amphotericin B. ( 27183429 )
2016
14
Canine Visceral Leishmaniasis in Wild Canines (Fox, Jackal, and Wolf) in Northeastern Iran Using Parasitological, Serological, and Molecular Methods. ( 28032106 )
2016
15
Mycobacterium indicus pranii (Mw)-mediated protection against visceral leishmaniasis by reciprocal regulation of host dual-specificity phosphatases. ( 28013190 )
2016
16
Comparative B-mode and Doppler renal ultrasonography with histopathological findings in dogs positive for canine visceral leishmaniasis. ( 27194210 )
2016
17
Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs. ( 27624408 )
2016
18
Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines. ( 28011960 )
2016
19
Visceral leishmaniasis triggering (mimicking) macrophage activation syndrome in a patient with adult onset Still disease. ( 27813355 )
2016
20
Treatment of visceral leishmaniasis: anomalous pricing and distribution of AmBisome and emergence of an indigenous liposomal amphotericin B, FUNGISOME. ( 27605844 )
2016
21
Suppression of host PTEN gene expression for Leishmania donovani survival in Indian visceral leishmaniasis. ( 26774334 )
2016
22
Acceptance and potential barriers to effective use of diagnostic tests for visceral leishmaniasis in an urban area in Brazil. ( 27192596 )
2016
23
Thick Smear is a Good Substitute for the Thin Smear in Parasitological Confirmation of Canine Visceral Leishmaniasis. ( 27162266 )
2016
24
Risk factors, representations and practices associated with emerging urban human visceral leishmaniasis in Posadas, Argentina. ( 27622625 )
2016
25
Correlations between peripheral parasite load and common clinical and laboratory alterations in dogs with visceral leishmaniasis. ( 27664450 )
2016
26
An 8-year retrospective study of human visceral leishmaniasis. ( 27659611 )
2016
27
Pancytopenia caused by visceral leishmaniasis in a patient immunosuppressed after cancer therapy. ( 27811190 )
2016
28
Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India. ( 27974858 )
2016
29
The Contribution of Immune Evasive Mechanisms to Parasite Persistence in Visceral Leishmaniasis. ( 27148272 )
2016
30
Elevated Serum ADA Activity as a Marker for Diagnosis and Prognosis of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis in Indian Patients. ( 27186641 )
2016
31
An rK28-Based Immunoenzymatic Assay for the Diagnosis of Canine Visceral Leishmaniasis in Latin America. ( 27162270 )
2016
32
Identification of Visceral Leishmaniasis-Susceptible Areas using Spatial Modelling in Southern Caucasus. ( 28026905 )
2016
33
Transgenic T cell-specific expression of CXCR3 enhances splenic and hepatic T cell accumulation but does not affect the outcome of visceral leishmaniasis. ( 27614845 )
2016
34
Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial. ( 27627654 )
2016
35
Pancytopenia during tyrosine kinase inhibitor treatment - coexistence of chronic myeloid leukemia and visceral leishmaniasis: a case report. ( 27461416 )
2016
36
Clinical and Microbiological Characteristics of Visceral Leishmaniasis Outbreak in a Northern Italian Nonendemic Area: A Retrospective Observational Study. ( 27999807 )
2016
37
Correction: Canine-Based Strategies for Prevention and Control of Visceral Leishmaniasis in Brazil. ( 27606898 )
2016
38
Recent updates and perspectives on approaches for the development of vaccines against visceral leishmaniasis. ( 27598624 )
2016
39
The Potential Use of Forensic DNA Methods Applied to Sand Fly Blood Meal Analysis to Identify the Infection Reservoirs of Anthroponotic Visceral Leishmaniasis. ( 27192489 )
2016
40
Occurrence of Lutzomyia longipalpis andhuman and canine cases of visceral leishmaniasis and evaluation of their expansion in the Northwest region of the State of SALo Paulo, Brazil. ( 27163563 )
2016
41
SLA-PGN primed dendritic cell based vaccination induces Th17 mediated protective immunity against experimental visceral leishmaniasis: a crucial role of PKCI^. ( 27150838 )
2016
42
Age structure of owned dogs under compulsory culling in a visceral leishmaniasis endemic area. ( 27598014 )
2016
43
Dispersal of Lutzomyia longipalpis and expansion of canine and human visceral leishmaniasis in SALo Paulo State, Brazil. ( 27640322 )
2016
44
Survey of feline visceral leishmaniasis in Azarshahr area, north west of Iran, 2013. ( 27605767 )
2016
45
The challenges on developing vaccine against visceral leishmaniasis. ( 27598623 )
2016
46
Detection of canine visceral leishmaniasis by conjunctival swab PCR. ( 27163572 )
2016
47
VISCERAL LEISHMANIASIS FROM AN AREA PREVIOUSLY NOT KNOWN TO BE ENDEMIC; DANGUR, BENSHANGUL-GUMUZ, REGIONAL STATE, NORTHWEST ETHIOPIA: A CASE REPORT. ( 27191028 )
2016
48
Therapeutic effect of ursolic acid in experimental visceral leishmaniasis. ( 27984757 )
2016
49
Cost-effectiveness analysis of diagnostic tests for human visceral leishmaniasis in Brazil. ( 27618920 )
2016
50
Detection of Leishmania donovani in peripheral blood of asymptomatic individuals in contact with patients with visceral leishmaniasis. ( 27198212 )
2016

Variations for Visceral Leishmaniasis

Expression for Visceral Leishmaniasis

Search GEO for disease gene expression data for Visceral Leishmaniasis.

Pathways for Visceral Leishmaniasis

Pathways related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 74)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.08 EEF2 IFNG IFNGR1 IL10 IL2 IL4
2
Show member pathways
13.71 IFNG IFNGR1 IL10 IL2 IL4 NOS2
3
Show member pathways
13.46 IL10 IL2 IL4 TGFB1 TLR2 TLR4
4
Show member pathways
13.42 IFNG IFNGR1 IL10 IL2 IL4 NOS2
5
Show member pathways
13.26 IFNG IFNGR1 IL2 IL4 TLR2 TLR4
6
Show member pathways
13 IFNG IFNGR1 IL10 IL2 NOS2 TGFB1
7
Show member pathways
12.93 FOXP3 IFNG IL10 IL2 IL4 TGFB1
8
Show member pathways
12.88 IFNG IFNGR1 IL2 IL4 TLR2 TLR4
9
Show member pathways
12.77 IL2 TGFB1 TLR2 TLR4 TLR9 TNF
10
Show member pathways
12.71 IFNG IFNGR1 IL10 IL2 IL4 TNF
11
Show member pathways
12.65 IFNG IL10 IL2 NOS2 TNF
12 12.65 FOXP3 IFNG IL10 IL2 IL4 TLR2
13
Show member pathways
12.6 FOXP3 IFNG IFNGR1 IL10 IL2 IL4
14
Show member pathways
12.58 IFNG IFNGR1 IL2 IL4 TNF
15
Show member pathways
12.52 IFNG IL10 IL2 IL4 TGFB1 TNF
16
Show member pathways
12.41 ALB IFNG IL2 IL4 TNF
17
Show member pathways
12.37 IFNG IL4 TLR2 TNF
18
Show member pathways
12.35 IFNG IFNGR1 NOS2 TLR4 TNF
19 12.34 TGFB1 TLR2 TLR4 TNF
20
Show member pathways
12.31 TLR2 TLR4 TLR9 TNF
21
Show member pathways
12.29 IFNG IFNGR1 IL10 IL2 IL4
22
Show member pathways
12.28 IFNG IFNGR1 IL4 NOS2 TLR2 TLR4
23
Show member pathways
12.25 IFNG IL10 IL2 IL4 TNF
24 12.25 IFNG IFNGR1 NOS2 TGFB1 TLR2 TLR4
25
Show member pathways
12.25 IFNG IFNGR1 IL10 IL4 NOS2 TGFB1
26 12.13 IFNG IL2 IL4 NOS2 TGFB1 TLR4
27 12.11 IFNG IFNGR1 TGFB1 TNF
28
Show member pathways
12.09 IL2 TLR2 TLR4 TLR9
29 12.09 IFNG IL10 IL2 IL4 TNF
30 12.08 IL10 IL4 NOS2 TGFB1 TNF
31 12.06 IFNG IFNGR1 IL10 NOS2 TGFB1 TLR2
32
Show member pathways
12.05 IFNG IL2 IL4 NOS2
33
Show member pathways
12.04 IFNG IL4 TGFB1 TLR2 TLR4 TLR9
34 12.02 IFNG IL10 NOS2 TGFB1 TLR2 TLR4
35 11.98 IFNG IFNGR1 NOS2 TLR4
36 11.96 IFNG TGFB1 TLR2 TLR4 TNF
37 11.92 IFNG IFNGR1 NOS2 TLR4
38 11.9 IFNG IL10 IL2 IL4 TNF
39 11.89 IL2 TGFB1 TLR4
40
Show member pathways
11.89 FOXP3 TGFB1 TLR4
41 11.89 IFNG IL10 IL2 TGFB1 TLR9 TNF
42
Show member pathways
11.87 FOXP3 IFNG IL2 IL4 TNF
43 11.85 TLR2 TLR4 TLR9
44 11.85 IL10 NOS2 TLR4 TNF
45 11.84 IFNG TGFB1 TNF
46 11.83 IFNG IL2 IL4
47 11.79 IFNG IFNGR1 IL10 IL2
48
Show member pathways
11.75 IFNG IL2 NOS2 TNF
49
Show member pathways
11.74 FOXP3 IL2 IL4
50 11.73 IFNG IL2 TGFB1

GO Terms for Visceral Leishmaniasis

Cellular components related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ALB EEF2 IFNG IL10 IL2 IL4
2 external side of plasma membrane GO:0009897 9.46 IFNG IL4 TLR4 TNF
3 extracellular space GO:0005615 9.28 ALB IFNG IL10 IL2 IL4 TGFB1

Biological processes related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

(show top 50) (show all 86)
id Name GO ID Score Top Affiliating Genes
1 response to virus GO:0009615 9.99 FOXP3 IFNG IFNGR1 TNF
2 cellular response to lipopolysaccharide GO:0071222 9.97 IFNG IL10 NOS2 TLR4 TNF
3 positive regulation of inflammatory response GO:0050729 9.95 IL2 TLR2 TLR4 TLR9
4 response to organic substance GO:0010033 9.94 IL10 TGFB1 TNF
5 negative regulation of inflammatory response GO:0050728 9.93 FOXP3 IL10 IL2
6 defense response to Gram-negative bacterium GO:0050829 9.93 NOS2 SLC11A1 TLR4 TLR9
7 regulation of insulin secretion GO:0050796 9.92 IFNG NOS2 TNF
8 positive regulation of JNK cascade GO:0046330 9.92 TLR4 TLR9 TNF
9 positive regulation of T cell proliferation GO:0042102 9.92 IFNG IL2 IL4
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.91 IFNG IL2 IL4
11 positive regulation of tumor necrosis factor production GO:0032760 9.91 IFNG TLR2 TLR4 TLR9
12 defense response to bacterium GO:0042742 9.91 IFNG IL10 NOS2 SLC11A1 TLR4 TLR9
13 toll-like receptor signaling pathway GO:0002224 9.9 TLR2 TLR4 TLR9
14 positive regulation of nitric oxide biosynthetic process GO:0045429 9.9 IFNG TLR4 TNF
15 extrinsic apoptotic signaling pathway GO:0097191 9.9 IFNG TGFB1 TNF
16 negative regulation of tumor necrosis factor production GO:0032720 9.89 FOXP3 IL10 TLR4
17 positive regulation of B cell proliferation GO:0030890 9.89 IL2 IL4 TLR4
18 positive regulation of interferon-gamma production GO:0032729 9.89 IL2 SLC11A1 TLR4 TNF
19 negative regulation of T cell proliferation GO:0042130 9.88 FOXP3 IL10 TGFB1
20 positive regulation of interleukin-6 production GO:0032755 9.88 TLR2 TLR4 TLR9 TNF
21 response to bacterium GO:0009617 9.87 NOS2 SLC11A1 TLR4
22 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.87 TLR2 TLR4 TLR9
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.87 TGFB1 TLR2 TLR4 TNF
24 protein import into nucleus, translocation GO:0000060 9.86 IFNG TGFB1 TNF
25 negative regulation of mitotic cell cycle GO:0045930 9.86 IL10 TGFB1 TNF
26 positive regulation of interferon-beta production GO:0032728 9.86 TLR2 TLR4 TLR9
27 positive regulation of gene expression GO:0010628 9.86 FOXP3 IFNG SLC11A1 TGFB1 TLR2 TLR4
28 negative regulation of interferon-gamma production GO:0032689 9.85 FOXP3 IL10 TLR4
29 positive regulation of protein complex assembly GO:0031334 9.85 IFNG TGFB1 TNF
30 positive regulation of interleukin-8 production GO:0032757 9.85 TLR2 TLR4 TLR9 TNF
31 negative regulation of growth of symbiont in host GO:0044130 9.84 IFNG IL10 TNF
32 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.83 TLR2 TLR4 TLR9
33 response to molecule of bacterial origin GO:0002237 9.83 IL10 TLR2 TLR9
34 I-kappaB phosphorylation GO:0007252 9.82 TLR2 TLR4 TLR9
35 regulation of cytokine secretion GO:0050707 9.81 TLR2 TLR4 TLR9
36 positive regulation of interleukin-12 production GO:0032735 9.81 IFNG TLR2 TLR4 TLR9
37 positive regulation of regulatory T cell differentiation GO:0045591 9.8 FOXP3 IL2 TGFB1
38 positive regulation of interleukin-10 production GO:0032733 9.8 IL4 TLR2 TLR4 TLR9
39 positive regulation of chemokine biosynthetic process GO:0045080 9.79 IFNG IL4 TNF
40 positive regulation of isotype switching to IgG isotypes GO:0048304 9.79 IFNG IL2 IL4
41 positive regulation of NF-kappaB import into nucleus GO:0042346 9.78 TLR2 TLR4 TLR9 TNF
42 microglial cell activation GO:0001774 9.76 IL4 TLR2
43 negative regulation of immune response GO:0050777 9.76 FOXP3 TGFB1
44 pentose-phosphate shunt GO:0006098 9.76 PGD TPI1
45 negative regulation of nitric oxide biosynthetic process GO:0045019 9.76 IL10 IL4
46 positive regulation of interleukin-17 production GO:0032740 9.76 IL2 TGFB1
47 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.76 IFNG IFNGR1
48 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.76 IL10 TNF
49 defense response to protozoan GO:0042832 9.76 IFNG IL10 IL4 SLC11A1
50 macrophage activation GO:0042116 9.75 SLC11A1 TLR4

Molecular functions related to Visceral Leishmaniasis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL2 IL4 TGFB1
2 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4
3 cytokine activity GO:0005125 9.1 IFNG IL10 IL2 IL4 TGFB1 TNF

Sources for Visceral Leishmaniasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....